Guttate psoriasis may represent the initial stage of chronic plaque-type psoriasis. On resolution, post-inflammatory hypo or hyperpigmentation may result. There is no scarring. Patients should be ...

Most patients with psoriasis experienced clinical improvement or remission after metabolic and bariatric surgery (MBS) in a ...

Discover a study in which researchers examined three international cohorts of patients with moderate-to-severe psoriasis ...

Starjemza (ustekinumab-hmny) was approved by the FDA this week as a biosimilar to Stelara. 2 A pair of clinical trials ...

Bimekizumab use for 4 years among patients with plaque psoriasis is associated with sustained efficacy outcomes and no new safety signals.

About 1 in 3 people with psoriasis who achieved clear skin with biologic drugs still had underlying inflammation that may ...

THURSDAY, May 29, 2025 (HealthDay News) — Belly flab appears to be a stronger warning sign for psoriasis than fat located ...

The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

This link between central fat and ... Mar. 3, 2025 — Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While previous treatment ...

Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.

Some of the same underlying triggers that drive psoriasis may also pose problems for your heart. There is strong evidence linking severe psoriasis with heart disease, but the exact relationship ...

BMS has previously said it reckons Sotyktu could become a $4 billion seller at its peak, fuelled by head-to-head studies showing it was more effective at treating moderate-to-severe psoriasis than ...